Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-28

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A

NCT05809687

Dyslipidemias

WITHDRAWN PHASE3

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

NCT05970679

Hypercholesterolemia, Dyslipidemia

COMPLETED PHASE3

Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid

NCT01974297

Mixed Hyperlipidemia

UNKNOWN NA

A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia

NCT04554953

Hypertension and Dyslipidemia

COMPLETED

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

NCT02899455

Hypertension Hyperlipidemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DP-R212 group

DP-R212 + C1-R212 placebo + C2-R212 placebo

Group Type EXPERIMENTAL

DP-R212

Intervention Type DRUG

DP-R212 + C1-R212 placebo + C2-R212 placebo

C1-R212 group

DP-R212 placebo + C1-R212 + C2-R212 placebo

Group Type ACTIVE_COMPARATOR

C1-R212

Intervention Type DRUG

DP-R212 placebo + C1-R212 + C2-R212 placebo

C2-R212 group

DP-R212 placebo + C1-R212 placebo + C2-R212

Group Type ACTIVE_COMPARATOR

C2-R212

Intervention Type DRUG

DP-R212 placebo + C1-R212 placebo + C2-R212

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DP-R212

DP-R212 + C1-R212 placebo + C2-R212 placebo

Intervention Type DRUG

C1-R212

DP-R212 placebo + C1-R212 + C2-R212 placebo

Intervention Type DRUG

C2-R212

DP-R212 placebo + C1-R212 placebo + C2-R212

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both man and woman who is over 19 years old
* Hypertension patient with hypercholesterolemia

Exclusion Criteria

* sSBP difference is ≥20mmHg or sDBP difference is ≥10mmHg
* A history of cardiovascular disease
* rhabdomyolysis, myopathy
* Hypertension or hypercholesterolemia due to secondary causes
* Uncontrolled diabetes
* Evidence of hepatic or renal disease

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No